Harnessing the B Cell Response in Kidney Transplantation – Current State and Future Directions

Despite dramatic improvement in kidney transplantation outcomes over the last decades due to advent of modern immunosuppressive agents, long-term outcomes remain poor. Antibody-mediated rejection (ABMR), a B cell driven process, accounts for the majority of chronic graft failures. There are currentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwar, Imran J., DeLaura, Isabel F., Gao, Qimeng, Ladowski, Joseph, Jackson, Annette M., Kwun, Jean, Knechtle, Stuart J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223638/
https://www.ncbi.nlm.nih.gov/pubmed/35757745
http://dx.doi.org/10.3389/fimmu.2022.903068
Descripción
Sumario:Despite dramatic improvement in kidney transplantation outcomes over the last decades due to advent of modern immunosuppressive agents, long-term outcomes remain poor. Antibody-mediated rejection (ABMR), a B cell driven process, accounts for the majority of chronic graft failures. There are currently no FDA-approved regimens for ABMR; however, several clinical trials are currently on-going. In this review, we present current mechanisms of B cell response in kidney transplantation, the clinical impact of sensitization and ABMR, the B cell response under current immunosuppressive regimens, and ongoing clinical trials for ABMR and desensitization treatment.

Ejemplares similares